GLPwatch
Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review
Curr Drug Saf · 2024
Last updated 2026-06-16| Journal | Curr Drug Saf, 2024 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.17 |
| NIH percentile | 11 |
| Molecules | tirzepatide |
Abstract
INTRODUCTION: Tirzepatide, a dual GIP and GLP-1 receptor agonist, is a promising therapeutic option for obesity and metabolic disorders.
METHODS: Systematic review following PRISMA guidelines across PubMed, Embase, and Cochrane. Included RCTs and observational studies.
RESULTS: Seven phase 3 trials showed significant, dose-dependent reductions in body weight and improvements in metabolic markers. Well-tolerated, with low rates of hypoglycemia. Subgroups with higher BMI had greater benefits.
DISCUSSION: Demonstrates consistent efficacy and safety across diverse populations; personalized approaches may optimize outcomes.
CONCLUSION: Tirzepatide is effective, safe, and durable in managing obesity and metabolic disorders; long-term studies warranted.
Verbatim abstract via PubMed 39484756 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.